Core Insights - On July 9, 2025, the top three companies by trading volume in the southbound Shanghai-Hong Kong Stock Connect were Giant Star Legend (06683), Guotai Junan International (01788), and Alibaba-W (09988) with trading volumes of 10.867 billion, 9.711 billion, and 4.349 billion respectively [1] - In the southbound Shenzhen-Hong Kong Stock Connect, the leading companies were Guotai Junan International (01788), Giant Star Legend (06683), and Alibaba-W (09988) with trading volumes of 3.649 billion, 3.320 billion, and 3.072 billion respectively [1] Southbound Shanghai-Hong Kong Stock Connect - The top active trading companies included: - Giant Star Legend (06683) with a trading amount of 10.867 billion and a net buying amount of +0.235 billion [2] - Guotai Junan International (01788) with a trading amount of 9.711 billion and a net buying amount of +0.175 billion [2] - Alibaba-W (09988) with a trading amount of 4.349 billion and a net buying amount of +1.038 billion [2] - Other notable companies included Tencent Holdings (00700) with a trading amount of 2.644 billion and a net selling amount of -48.5393 million [2] Southbound Shenzhen-Hong Kong Stock Connect - The top active trading companies included: - Guotai Junan International (01788) with a trading amount of 3.649 billion and a net buying amount of +0.631176 billion [2] - Giant Star Legend (06683) with a trading amount of 3.320 billion and a net buying amount of +0.155 billion [2] - Alibaba-W (09988) with a trading amount of 3.072 billion and a net selling amount of -24.5399 million [2] - Other notable companies included Tencent Holdings (00700) with a trading amount of 1.311 billion and a net buying amount of +0.877015 billion [2]

Market Overview - Southbound funds traded approximately 132.6 billion HKD today, accounting for 56.72% of the total turnover of the Hang Seng Index, indicating a short-term high in market share [2] - Despite a pullback in the Hang Seng Index, there are signs of increased investment as southbound funds recorded a net inflow of approximately 9.256 billion HKD, with 6.585 billion HKD from the Shanghai-Hong Kong Stock Connect and 2.672 billion HKD from the Shenzhen-Hong Kong Stock Connect [2] Individual Stock Performance - China Construction Bank (00939.HK) saw a net buy of 1.1 billion HKD, with a slight decline of 0.24% today and a total of 162 million shares added over the past five days [3][4] - Alibaba Group (9988.HK) experienced a net buy of 1.014 billion HKD, but its stock fell by 3.83%, with a reduction of 65.55 million shares over the last five days [3][4] - Meituan (03690.HK) had a net buy of 833 million HKD, with a decline of 2.46% today and an increase of 1.222 million shares over the past five days [3][4] - Xiaomi Group (01810.HK) recorded a net buy of 422 million HKD, with a drop of 2.13% and a reduction of 2.166 million shares in the last five days [3][4] - Legend Holdings (06683.HK) surged by 94.38%, with a net buy of 389 million HKD and an increase of 398,000 shares over the past five days [3][4] - China National Pharmaceutical Group (01177.HK) rose by 10.06%, with a net buy of 309 million HKD and an increase of approximately 10 million shares in the last five days [3][4] Trading Activity - The top active stocks in the southbound trading included Legend Holdings, which had a net inflow of 2.35 billion HKD, and Alibaba, which saw a net outflow of 10.38 billion HKD [5][6] - Over the past month, the total net inflow from southbound trading reached approximately 87.399 billion HKD, with 39.341 billion HKD from the Shanghai Stock Connect and 48.058 billion HKD from the Shenzhen Stock Connect [5]

Group 1: Market Overview - Northbound trading recorded a net buy of 92.56 billion HKD on July 9, with 65.85 billion HKD from Shanghai Stock Connect and 26.72 billion HKD from Shenzhen Stock Connect [1] - The most net bought stocks included China Construction Bank (00939), Alibaba-W (09988), and Meituan-W (03690) [1] Group 2: Stock Performance - China Construction Bank (00939) saw a net inflow of 10.99 billion HKD, with analysts predicting a steady upward trend in the banking sector for Q3 due to long-term capital support [4] - Alibaba-W (09988) and Meituan-W (03690) received net buys of 10.13 billion HKD and 8.33 billion HKD respectively, with positive outlooks on their business strategies amid competitive pressures [5] - Xiaomi Group-W (01810) had a net buy of 4.21 billion HKD, with expectations of increasing profit margins in its electric vehicle business [5] - Legend Holdings (06683) attracted a net buy of 3.89 billion HKD following news of a major celebrity's engagement with the brand [5] - China Biologic Products (01177) received a net buy of 3.08 billion HKD after announcing the approval of a new product for hemophilia treatment [6] Group 3: Other Notable Stocks - Other stocks with significant net inflows included Semiconductor Manufacturing International Corporation (00981) with 2.4 billion HKD, Tencent (00700) with 391.6 million HKD, and Hong Kong Travel (00308) with 183 million HKD [7]

南向资金今日大幅净买入92.56亿元。港股通（沪）方面，建设银行、阿里巴巴-W分别获净买入11.0亿 港元、10.38亿港元；腾讯控股净卖出额居首，金额为0.49亿港元；港股通（深）方面，中国生物制药、 中芯国际分别获净买入3.09亿港元、2.55亿港元；阿里巴巴-W净卖出额居首，金额为0.25亿港元。 ...

Core Viewpoint - The recent announcement by President Trump regarding potential high tariffs on copper and pharmaceuticals has led to a decline in Hong Kong's stock market, with the Hang Seng Index falling below 24,000 points, reflecting increased macroeconomic risks and impacting market sentiment [1][4]. Market Performance - The Hang Seng Index closed down 1.06% at 23,892.32 points, with a total trading volume of 233.88 billion HKD. The Hang Seng China Enterprises Index fell 1.28%, while the Hang Seng Tech Index dropped 1.76% [1]. - Major blue-chip stocks experienced significant movements, with Henderson Land Development leading the decline, down 8.64% at 25.9 HKD, while China Biologic Products rose 10.06% to 5.91 HKD [2]. Sector Analysis - The technology sector saw a collective decline, with Alibaba down nearly 4% and Tencent over 1%. The copper sector was negatively impacted by Trump's tariff threats, leading to a drop in copper-related stocks [3][6]. - The innovative drug sector performed well, with Hengrui Medicine surging 15.61% to 69.6 HKD, indicating resilience amid broader market declines [3][4]. Specific Stock Movements - Macau's gaming sector showed strong performance, with Wynn Macau up 6.33% and Melco Resorts up 2.12%, driven by robust gaming revenue growth [4][5]. - Copper stocks faced significant declines, with Luoyang Molybdenum down 4.74% and Jiangxi Copper down 3.46%, reflecting market reactions to tariff announcements [5][6]. Commodity Prices - International gold prices fell below 3,300 USD per ounce, influenced by reduced safe-haven demand amid tariff uncertainties. Analysts expect gold prices to remain volatile within a range of 3,000 to 3,500 USD per ounce [7].

Group 1 - The Hang Seng Index closed down 1.06%, while the Hang Seng Tech Index fell by 1.76% [1] - The innovative drug sector saw significant gains, with Hengrui Medicine (01276.HK) rising over 15% and China Biologic Products (01177.HK) increasing by more than 10% [1] - Education stocks strengthened during the midday session, with China Oriental Education (00667.HK) up over 3% [1] Group 2 - Rare earth stocks rebounded towards the end of the trading day, with Jinli Permanent Magnet rising over 2% [1] - Other sectors such as cement and building materials, biomedicine, environmental protection, and oil saw gains [1] - Gold, stablecoins, nuclear power, non-ferrous metals, and chips experienced declines during the day [1] Group 3 - On the individual stock front, Lens Technology (06613.HK) rose 9% on its first trading day, while "Jay Chou concept stock" Superstar Legend (06683.HK) surged 94%, surpassing a market capitalization of 10 billion HKD [1] - Guotai Junan International (01788.HK) fell by over 5% [1]

Core Viewpoint - The pharmaceutical sector in Hong Kong is experiencing a strong resurgence, particularly driven by leading companies like Heng Rui Pharmaceutical, despite external pressures from potential U.S. tariffs on drugs [2][11]. Group 1: Market Performance - A-shares are showing strong performance with sectors like "anti-involution," photovoltaic, computing power, and military industries rising, while the Hang Seng Index is declining [1]. - Heng Rui Pharmaceutical's stock surged over 14% in Hong Kong, reaching a new high since July 2021, with a market capitalization of HKD 453.65 billion [5][6]. Group 2: Company Developments - Heng Rui Pharmaceutical is a leader in the pharmaceutical industry, covering various therapeutic areas including oncology, metabolism, cardiovascular diseases, and more [7]. - The company received approval for clinical trials for two new drugs, indicating its role as an innovator in the pharmaceutical sector [8]. Group 3: Analyst Insights - Citigroup has initiated a buy rating for Heng Rui Pharmaceutical's H-shares with a target price of HKD 134, highlighting the company's growth potential [9]. - Revenue growth predictions for Heng Rui Pharmaceutical are optimistic, with expected increases of 27%, 18%, and 18% from 2025 to 2027, along with net profit growth of 39%, 23%, and 17% [10].

Group 1 - The core viewpoint of the articles highlights the strong performance of the Hong Kong innovative pharmaceutical sector, with significant gains in the Hong Kong Innovative Drug 50 ETF and individual stocks like Boan Biotechnology and Tigermed [1][2] - As of July 8, the top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 68% of the total weight, including high-quality A-share companies like Innovent Biologics and CSPC Pharmaceutical Group [2] - The National Medical Products Administration reported that in the first half of the year, 43 innovative drugs and 45 innovative medical devices were approved, representing year-on-year increases of 59% and 87% respectively, indicating a positive trend in the industry [1] Group 2 - The innovative pharmaceutical sector in China is at a new historical starting point, with domestic companies enhancing their competitiveness and expanding overseas, supported by strong policy backing [2] - The net inflow into the Hong Kong Innovative Drug 50 ETF reached 573 million yuan in the last three months and 851 million yuan year-to-date, reflecting investor confidence in the sector [1] - Guotai Junan Securities expresses strong confidence in a reversal in the pharmaceutical sector by 2025, emphasizing investment opportunities in innovative drugs addressing unmet clinical needs and medical devices [1]

Core Viewpoint - The innovative drug sector is experiencing a strong rally, with significant growth potential driven by global business development (BD) authorizations and advanced technology platforms [3][4]. Group 1: Industry Trends - The innovative drug market is expected to see continuous BD authorizations, which are crucial for driving the next wave of growth and revenue [3]. - Advanced technology platforms such as ADC, bispecific antibodies, and CAR-T are leading the innovation in the post-PD-1 era, positioning Chinese innovative drug companies at the forefront globally [3]. - China is leading in the ADC field, with a significant number of reports presented at ASCO, indicating a strong presence in the global market [3]. - The bispecific antibody pipeline in China accounts for nearly 50% of the global pipeline, with impressive clinical data and a projected 14 products expected to enter international markets in 2024, surpassing $10 billion in total transaction value [3]. Group 2: Upcoming Events and Opportunities - Key industry conferences such as WCLC and ESMO are anticipated to showcase the latest clinical research from Chinese innovative drug companies, serving as potential catalysts for the sector [4]. - High-demand disease areas, including weight loss and autoimmune diseases, present significant unmet clinical needs, offering expansive future market opportunities [4]. - Policy support, including optimization of medical insurance access and the introduction of new categories, is crucial for the continued growth of the innovative drug sector [4]. Group 3: Investment Strategies - The innovative drug sector is viewed as a long-term investment opportunity, with public funds gradually recovering after previous declines [5]. - Investors are encouraged to adopt a strategy of buying on dips, particularly focusing on the innovative drug ETF from Guotai (517110), which provides a balanced exposure to major innovative drug companies across A-shares and Hong Kong stocks [5]. - Notable companies in the innovative drug space include Heng Rui Medicine, King’s Ray Biotechnology, BeiGene, and others, which are recommended for consideration [5].

Market Overview - The A-share market experienced an overall upward trend, with major indices rising, particularly the Shanghai Composite Index, which returned to the 3500-point level for the first time in 8 months, reaching a peak of 3512.67 points during the session [1][4][3] - The ChiNext Index also saw gains, surpassing the 2200-point mark with an increase of over 1% [6] Sector Performance - Among the sectors classified by Shenwan, the top-performing sectors included Media, Electric Equipment, Food & Beverage, Agriculture, Forestry, Animal Husbandry & Fishery, and Beauty & Personal Care, while sectors such as Non-ferrous Metals, Steel, and Basic Chemicals lagged behind [8] Concept Stocks - The short drama game concept sector led the market with a rise of over 2%, with stocks like Huanrui Century and Zhangyue Technology hitting the daily limit [9] Individual Stocks - Guotou Zhonglu has seen its stock hit the daily limit for three consecutive trading days, as the company announced plans to acquire 100% of China Electronics Engineering Design Institute's shares through a share issuance [10][11] - In the Hong Kong market, Hillstone Technology surged over 12%, driven by positive sales data for its camera modules, which showed a year-on-year increase of 4.1% [12][15] Futures Market - In the domestic futures market, the main contract for polysilicon surged, with an intraday increase of over 6%. The price approached 39,800 yuan/ton, marking a nearly 30% increase over the past 10 trading days [2][17][16]